G&A at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s G&A?
- Artiva Biotherapeutics, Inc. (ARTV) reported G&A of $5.12M in Q1 2026.
- How has Artiva Biotherapeutics, Inc.'s G&A changed year-over-year?
- Artiva Biotherapeutics, Inc.'s G&A decreased by 0.0% year-over-year, from $5.12M to $5.12M.
- What is the long-term trend for Artiva Biotherapeutics, Inc.'s G&A?
- Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s G&A has grown at a 20.7% compound annual growth rate (CAGR), from $13.91M to $20.27M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.